Kebudi, RejinKurucu, NilgünTuğcu, DenizHacısalihoğlu, SadanFışgın, TunçOcak, SüheylaKara, AteşBozkurt, CeyhunInce, DilekAras, SedaAycicek, AliAksoy, Basak AdakliKaradas, NihalOzturk, GulyuzOrhan, Mehmet FatihAtaseven, EdaAkbayram, SinanYilmaz, EbruTufekci, OzlemVural, SemaAkyay, ArzuAyhan, Aylin CanbolatKilic, SuarUzel, Veysiye HulyaDuzenli, YeterAcipayam, CanElli, MuratTanyeli, AtillaKarakas, ZeynepSomer, AyperKara, Ates2021-05-152021-05-1520211545-50091545-5017https://doi.org/10.1002/pbc.28915https://hdl.handle.net/20.500.12939/111Aksoy, Basak Adakli/0000-0001-8338-2101; Ozdemir, Nihal/0000-0002-3204-4353Adults with cancer are reported to have a higher risk for coronavirus disease (COVID-19) infection and more severe disease and mortality than the general population.1,2 Although children seem to be at a lower risk for COVID-19 than adults,3–5 data specifically addressing children with cancer are limited.6–12 We conducted a retrospective, multicenter, cross-sectional study on behalf of the Turkish Pediatric Hematology Society (TPHD) and Turkish Pediatric Oncology Group (TPOG) Society to analyze the characteristics of COVID-19 in all patients with cancer and stem cell transplant (SCT) recipients in all centers in Turkey, during March 11-May 31, 2020. Approval for the study was obtained by Turkish Ministry of Health (MoH), Istanbul University COVID Scientific Research Committee, and Istanbul University Ethics Committee. The study was carried out through the analysis of a questionnaire with 62 questions, which was sent to all members of the TPOG and TPHD Societies working in all 66 pediatric hematology/oncology departments in university, state, and private hospitals in Turkey. All replied and 53 patients were reported from the 24 centers.eninfo:eu-repo/semantics/closedAccessCOVID-19TurkeyChildren With CancerCell Transplant RecipientsLetter10.1002/pbc.28915686335381002-s2.0-85100509840Q1WOS:000614296900001Q1